Cargando…

Biliary effects of liraglutide and sitagliptin, a 12‐week randomized placebo‐controlled trial in type 2 diabetes patients

AIMS: Treatment with glucagon‐like peptide (GLP)‐1 receptor agonists or dipeptidyl peptidase (DPP)‐4 inhibitors might increase gallstone formation; however, the mechanisms involved are unknown. We aimed to assess the effects of these drugs on gallbladder volume and bile acid profile. MATERIALS AND M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smits, Mark M., Tonneijck, Lennart, Muskiet, Marcel H.A., Hoekstra, Trynke, Kramer, Mark H.H., Diamant, Michaela, Nieuwdorp, Max, Groen, Albert K., Cahen, Djuna L., van Raalte, Daniël H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129471/ https://www.ncbi.nlm.nih.gov/pubmed/27451030 http://dx.doi.org/10.1111/dom.12748

Ejemplares similares

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
por: Smits, Mark M., et al.
Publicado: (2016)

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes
por: Smits, Mark M, et al.
Publicado: (2015)

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050
por: Tonneijck, Lennart, et al.
Publicado: (2019)

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
por: Tonneijck, Lennart, et al.
Publicado: (2016)

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
por: Sivalingam, Suvanjaa, et al.
Publicado: (2021)

Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes
por: Smits, M. M., et al.
Publicado: (2017)

Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial
por: Kraaijenhof, Jordan, et al.
Publicado: (2020)

Plasma uric acid and renal haemodynamics in type 2 diabetes patients
por: Suijk, Danii LS, et al.
Publicado: (2019)

Renal sinus fat and renal hemodynamics: a cross-sectional analysis
por: Spit, Karlinde A., et al.
Publicado: (2019)

Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double‐blind trial
por: Muskiet, Marcel H. A., et al.
Publicado: (2021)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
por: van Ruiten, Charlotte C., et al.
Publicado: (2022)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Liraglutide Treatment in a Patient With HIV and Uncontrolled Insulin-Treated Type 2 Diabetes
por: Diamant, Michaela, et al.
Publicado: (2012)

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26‐week, open‐label, randomized, active comparator clinical trial
por: Zang, L., et al.
Publicado: (2016)

Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin
por: Mezquita Raya, Pedro, et al.
Publicado: (2013)

The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
por: Ohki, Takamasa, et al.
Publicado: (2012)

Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment
por: Best, Jennie H., et al.
Publicado: (2011)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross‐sectional study
por: Bouman, Emma J., et al.
Publicado: (2021)

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA‐SWITCH): a randomized, double‐blind, double‐dummy, active‐controlled 26‐week trial
por: Bailey, T. S., et al.
Publicado: (2016)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

Divergent Effects of Liraglutide, Exendin-4, and Sitagliptin on Beta-Cell Mass and Indicators of Pancreatitis in a Mouse Model of Hyperglycaemia
por: Mondragon, Angeles, et al.
Publicado: (2014)

Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States
por: Li, Qian, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
por: Pérez, Antonio, et al.
Publicado: (2015)

Effects of COVID-19 on diabetes care among dutch diabetes outpatients
por: Bak, Jessica C.G., et al.
Publicado: (2023)

Design and rationale of the IN CONTROL trial: the effects of real-time continuous glucose monitoring on glycemia and quality of life in patients with type 1 diabetes mellitus and impaired awareness of hypoglycemia
por: van Beers, Cornelis A.J., et al.
Publicado: (2015)

Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial
por: van Raalte, D. H., et al.
Publicado: (2011)

Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years
por: Li, Qian, et al.
Publicado: (2018)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis
por: Li, Mingxing, et al.
Publicado: (2017)

Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden
por: Lind, Marcus, et al.
Publicado: (2016)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

A budget impact analysis of substituting sitagliptin with liraglutide in type 2 diabetes from a private health insurance perspective in Egypt
por: Elsisi, Gihan Hamdy, et al.
Publicado: (2022)

Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Liraglutide-Induced Hepatotoxicity
por: Maor, Yaakov, et al.
Publicado: (2021)

Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial
por: Pratley, Richard E., et al.
Publicado: (2012)

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fad47vog6k6ev16ng3jnlhvpdq